While Zika is no longer in the public eye, it hasn’t vanished. Recent outbreaks across Asia and Africa are reminders that Zika is alive and well, and with no effective countermeasures available, little can be done for mothers at risk of infection. A major gap in our protective arsenal is a lack of sensitive and accurate diagnostics. Immunoassay development has been severely hampered by cross-reactive antibodies. Dr Andy Lane at The Native Antigen Company discusses why new approaches to the production of reagents and assay design are required.